The year 2016 has been quite an exciting one for the Indian pharmaceutical industry. The market clocked an impressive compounded annual growth rate of 17.46% over the period 2005-2016. By 2020, the Indian pharmaceutical market is expected to be among the global top three by incremental growth and is expected to be the sixth largest market in the world in terms of absolute size.
According to the WHO, at the end of 2015, there were approximately 36.7 million people living with HIV with 2.1 million people becoming newly infected with HIV in 2015 globally. Yet the WHO also states that between 2000 and 2015, new HIV infections have fallen by 35%, AIDS-related deaths have fallen by 28% with some 7.8 million lives saved as a result of international efforts.
Clinical research in India may soon get a much-needed boost. The Indian Council of Medical Research (ICMR) and drug maker Sun Pharma are in talks to create a structure to fund clinical programmes focused on diseases prevalent here. A joint working group under the existing ICMR-Sun Pharma partnership met on Thursday to discuss avenues to improve innovation in the country through “well-characterised” sites to conduct disease burden studies and clinical trials.